An expert clinician expands on efficacy results seen in a study comparing intravenous and subcutaneous biologics.
Video content above is prompted by the following:
Trispecific Antibodies Show Promise in Treating Cancer and Other Diseases
September 11th 2024Pharmaceutical companies are making investments in research of therapies that target three different antigen-binding sites. Trispecific antibody research is still in its earliest phases and is focused on applications in cancer, inflammatory conditions and infectious diseases.
Read More